Scholar Rock Holding (SRRK) Cash from Operations (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Cash from Operations of 82101000.0 for Q1 2026, down 4.35% year-over-year from 85838963.64 in Q1 2025, and down 8.75% quarter-over-quarter from 75496000.0 in Q4 2025.
Powered by 
Analysis
Scholar Rock Holding (SRRK) Cash from Operations (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Cash from Operations history runs 10 years deep, the most recent figure standing at 82101000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 4.35% year-over-year to 82101000.0; the TTM figure through Mar 2026 stood at 303461000.0 (down 32.03% YoY), while the FY2025 annual figure was 300035000.0, down 49.31% from the prior year.
- Cash from Operations for Q1 2026 stood at 82101000.0, down from 75496000.0 in the prior quarter.
- The five-year high for Cash from Operations was 26483000.0 in Q3 2022, with the low at 82101000.0 in Q1 2026.
- The 5-year median for Cash from Operations is 49196000.0 (2024), against an average of 50647352.94.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations grew 26.39% in 2022, then plunged 62.54% in 2024.
- Scholar Rock Holding's Cash from Operations stood at 28907000.0 in 2022, then decreased by 29.2% to 37349000.0 in 2023, then sank by 32.57% to 49513000.0 in 2024, then slumped by 52.48% to 75496000.0 in 2025, then dropped by 8.75% to 82101000.0 in 2026.
- Business Quant data shows SRRK's Cash from Operations at 82101000.0 in Q1 2026, 75496000.0 in Q4 2025, and 68923000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Scholar Rock Holding | 7.24 Bn | 7.24 Bn | - | -70.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -70.31 Mn |
| Mar 31, 2026 | -82.10 Mn |
| Dec 31, 2025 | -75.50 Mn |
| Sep 30, 2025 | -68.92 Mn |
| Jun 30, 2025 | -76.94 Mn |
| Mar 31, 2025 | -78.68 Mn |
| Dec 31, 2024 | -49.51 Mn |
| Sep 30, 2024 | -52.46 Mn |
| Jun 30, 2024 | -49.20 Mn |
| Mar 31, 2024 | -49.79 Mn |
| Dec 31, 2023 | -37.35 Mn |
| Sep 30, 2023 | -32.27 Mn |
| Jun 30, 2023 | -32.55 Mn |
| Mar 31, 2023 | -43.05 Mn |
| Dec 31, 2022 | -28.91 Mn |
| Sep 30, 2022 | -26.48 Mn |
| Jun 30, 2022 | -34.74 Mn |
| Mar 31, 2022 | -42.57 Mn |
| Dec 31, 2021 | -32.46 Mn |
| Sep 30, 2021 | -35.98 Mn |